2023 Approvals

Male doctor and male patient

2023 Approvals

FDA Approves Fruzaqla: A New Hope for Metastatic Colorectal Cancer Patients, Approved November 8, 2023

What is Fruzaqla prescribed for? Fruzaqla is prescribed for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. What is Fruzaqla and

By B Jamerson